| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 149K | 868K | 711K | 67.25M | 1.1B | 1.62B | 86.18M | 74.2M |
| Revenue Growth % | - | 4.83% | -0.18% | 93.58% | 15.29% | 0.48% | -0.95% | -0.14% |
| Cost of Goods Sold | 62.51M | 100.23M | 0 | 0 | 513.87M | 620.97M | 572.83M | 478.64M |
| COGS % of Revenue | 419.54% | 115.47% | - | - | 0.47% | 0.38% | 6.65% | 6.45% |
| Gross Profit | -62.36M | -99.36M | 711K | 67.25M | 581.54M | 994.83M | -486.65M | -404.44M |
| Gross Margin % | -418.54% | -114.47% | 1% | 1% | 0.53% | 0.62% | -5.65% | -5.45% |
| Gross Profit Growth % | - | -0.59% | 1.01% | 93.58% | 7.65% | 0.71% | -1.49% | 0.17% |
| Operating Expenses | 81.65M | 119.56M | 178.69M | 364.23M | 160.79M | 161.76M | 197.66M | 182.72M |
| OpEx % of Revenue | 547.96% | 137.74% | 251.32% | 5.42% | 0.15% | 0.1% | 2.29% | 2.46% |
| Selling, General & Admin | 21.69M | 29.13M | 37.6M | 70.94M | 0 | 0 | 0 | 0 |
| SG&A % of Revenue | 145.59% | 33.56% | 52.88% | 1.05% | - | - | - | - |
| Research & Development | 62.51M | 100.23M | 148.47M | 302.41M | 448.01M | 474.65M | 579.72M | 506.5M |
| R&D % of Revenue | 419.54% | 115.47% | 208.82% | 4.5% | 0.41% | 0.29% | 6.73% | 6.83% |
| Other Operating Expenses | 83K | -212K | -7.38M | -9.12M | -287.21M | -312.89M | -382.06M | -323.77M |
| Operating Income | -81.5M | -118.69M | -177.98M | -296.98M | 420.75M | 833.07M | -684.3M | -587.16M |
| Operating Margin % | -546.96% | -136.74% | -250.32% | -4.42% | 0.38% | 0.52% | -7.94% | -7.91% |
| Operating Income Growth % | - | -0.46% | -0.5% | -0.67% | 2.42% | 0.98% | -1.82% | 0.14% |
| EBITDA | -81.06M | -115.94M | -173.46M | -291.54M | 426.56M | 839.85M | -664.85M | -572.61M |
| EBITDA Margin % | -544.06% | -133.57% | -243.97% | -4.34% | 0.39% | 0.52% | -7.71% | -7.72% |
| EBITDA Growth % | - | -0.43% | -0.5% | -0.68% | 2.46% | 0.97% | -1.79% | 0.14% |
| D&A (Non-Cash Add-back) | 432K | 2.76M | 4.52M | 5.44M | 5.81M | 6.78M | 19.45M | 14.56M |
| EBIT | -81.5M | -118.69M | -177.98M | -296.98M | 420.75M | 833.07M | -661.09M | -523.47M |
| Net Interest Income | 638K | 2.54M | 8.51M | 2.84M | 439K | 28.09M | 86.99M | 71.81M |
| Interest Income | 638K | 2.54M | 8.51M | 2.84M | 439K | 28.09M | 86.99M | 71.81M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 721K | 2.33M | 3.45M | -1.63M | 129.05M | -78.79M | 56.11M | 64.06M |
| Pretax Income | -80.78M | -116.36M | -174.53M | -298.61M | 549.8M | 754.28M | -628.19M | -523.11M |
| Pretax Margin % | -542.12% | -134.06% | -245.47% | -4.44% | 0.5% | 0.47% | -7.29% | -7.05% |
| Income Tax | -10.92M | -480K | 154K | 54K | 21.22M | 238.44M | -13.08M | -1.15M |
| Effective Tax Rate % | 0.86% | 1% | 1% | 1% | 0.96% | 0.68% | 0.98% | 1% |
| Net Income | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.06M | -521.96M |
| Net Margin % | -468.81% | -133.51% | -245.69% | -4.44% | 0.48% | 0.32% | -7.14% | -7.03% |
| Net Income Growth % | - | -0.66% | -0.51% | -0.71% | 2.77% | -0.02% | -2.19% | 0.15% |
| Net Income (Continuing) | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.12M | -521.96M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.02 | -1.20 | -1.62 | -2.51 | 3.96 | 3.83 | -4.59 | -3.83 |
| EPS Growth % | - | 0.88% | -0.35% | -0.55% | 2.58% | -0.03% | -2.2% | 0.17% |
| EPS (Basic) | -10.02 | -1.20 | -1.62 | -2.51 | 4.07 | 3.89 | -4.59 | -3.83 |
| Diluted Shares Outstanding | 6.97M | 96.91M | 107.65M | 119.16M | 133.44M | 134.81M | 134.13M | 136.25M |
| Basic Shares Outstanding | 6.97M | 96.91M | 107.65M | 119.16M | 129.88M | 132.61M | 134.13M | 136.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 192.35M | 117.78M | 403M | 772.37M | 1.56B | 2.52B | 1.59B | 1.04B |
| Cash & Short-Term Investments | 187.92M | 98.44M | 383.44M | 736.86M | 708.14M | 2.4B | 1.52B | 905.35M |
| Cash Only | 187.92M | 47.6M | 109.33M | 436.57M | 347.81M | 848.63M | 241.58M | 222.95M |
| Short-Term Investments | 0 | 50.84M | 274.1M | 300.29M | 360.33M | 1.55B | 1.28B | 682.4M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 773.08M | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | 257.6 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 10.76M | 6.18M | 7.99M | 8.59M | 59.2M | 65.82M | 137.11M |
| Total Non-Current Assets | 59.22M | 73.81M | 109.04M | 146.4M | 391.45M | 283.01M | 330.83M | 356.33M |
| Property, Plant & Equipment | 5.14M | 12.29M | 16.31M | 79.89M | 130.05M | 188.17M | 167.2M | 122.86M |
| Fixed Asset Turnover | 0.03x | 0.07x | 0.04x | 0.84x | 8.42x | 8.59x | 0.52x | 0.60x |
| Goodwill | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M |
| Intangible Assets | 35.88M | 36.92M | 35.66M | 33.82M | 33.29M | 32.76M | 22.57M | 8.1M |
| Long-Term Investments | 1M | 7.67M | 24.29M | 0 | 201.39M | 23.93M | 105.28M | 190.01M |
| Other Non-Current Assets | 1.26M | 7.67M | 15.85M | 15.75M | 9.78M | -228.5M | 18.86M | 18.42M |
| Total Assets | 251.57M | 191.6M | 512.07M | 918.76M | 1.95B | 2.8B | 1.92B | 1.4B |
| Asset Turnover | 0.00x | 0.00x | 0.00x | 0.07x | 0.56x | 0.58x | 0.04x | 0.05x |
| Asset Growth % | - | -0.24% | 1.67% | 0.79% | 1.13% | 0.43% | -0.32% | -0.27% |
| Total Current Liabilities | 12.44M | 39.91M | 59.21M | 99.06M | 341.24M | 511.03M | 175.41M | 119.66M |
| Accounts Payable | 4.9M | 6.47M | 5.88M | 5.08M | 6.52M | 6.42M | 6.33M | 5.08M |
| Days Payables Outstanding | 28.6 | 23.57 | - | - | 4.63 | 3.77 | 4.04 | 3.87 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 0 | 22.02M | 22.08M | 10.6M | 0 | 7.65M | 9.35M | 16.06M |
| Current Ratio | 15.46x | 2.95x | 6.81x | 7.80x | 4.58x | 4.93x | 9.05x | 8.71x |
| Quick Ratio | 15.46x | 2.95x | 6.81x | 7.80x | 4.58x | 4.93x | 9.05x | 8.71x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 308.04M | 330.87M | 28.92M | 102.84M | 181.18M | 213.1M | 153.42M | 128.77M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 66.56M | 133.56M | 123.84M | 111.67M | 90.14M |
| Deferred Tax Liabilities | 3.31M | 3.31M | 3.31M | 3.25M | 18.44M | 3.25M | 0 | 0 |
| Other Non-Current Liabilities | 10.4M | 10.84M | 12.95M | 29.22M | 25.36M | 32.8M | 40.22M | 38.63M |
| Total Liabilities | 320.48M | 370.77M | 88.13M | 201.91M | 522.42M | 724.13M | 328.82M | 248.43M |
| Total Debt | 0 | 10.14M | 237K | 70.18M | 137.49M | 127.97M | 124.54M | 97.89M |
| Net Debt | -187.92M | -37.46M | -109.1M | -366.39M | -210.33M | -720.66M | -117.04M | -125.06M |
| Debt / Equity | - | - | 0.00x | 0.10x | 0.10x | 0.06x | 0.08x | 0.09x |
| Debt / EBITDA | - | - | - | - | 0.32x | 0.15x | - | - |
| Net Debt / EBITDA | - | - | - | - | -0.49x | -0.86x | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -68.92M | -179.18M | 423.94M | 716.85M | 1.43B | 2.08B | 1.59B | 1.15B |
| Equity Growth % | - | -1.6% | 3.37% | 0.69% | 1% | 0.45% | -0.23% | -0.28% |
| Book Value per Share | -9.88 | -1.85 | 3.94 | 6.02 | 10.73 | 15.41 | 11.86 | 8.44 |
| Total Shareholders' Equity | -68.92M | -179.18M | 423.94M | 716.85M | 1.43B | 2.08B | 1.59B | 1.15B |
| Common Stock | 1K | 1K | 11K | 13K | 13K | 13K | 13K | 14K |
| Retained Earnings | -77.95M | -193.84M | -368.52M | -667.18M | -138.6M | 377.24M | -237.82M | -759.78M |
| Treasury Stock | 0 | -14.67M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -292.52M | -14K | -601K | -1.28M | -1.1M | -9.12M | -815K | -1.72M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -66.38M | -94.1M | -129.63M | -190.94M | -47.59M | 1.66B | -778.78M | -446.35M |
| Operating CF Margin % | -445.51% | -108.41% | -182.32% | -2.84% | -0.04% | 1.03% | -9.04% | -6.02% |
| Operating CF Growth % | - | -0.42% | -0.38% | -0.47% | 0.75% | 35.95% | -1.47% | 0.43% |
| Net Income | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.06M | -521.96M |
| Depreciation & Amortization | 432K | 2.76M | 4.52M | 5.44M | 5.81M | 6.78M | 19.45M | 14.56M |
| Stock-Based Compensation | 4.78M | 5.05M | 8.72M | 27.6M | 83.78M | 102.08M | 0 | 78.46M |
| Deferred Taxes | -10.92M | -480K | 0 | -52K | 15.19M | -15.19M | -1.06M | -2.95M |
| Other Non-Cash Items | 4.32M | 1.97M | 23.61M | 45.21M | -52.56M | 388.37M | 122.48M | 69.55M |
| Working Capital Changes | 4.86M | 12.49M | 8.2M | 29.52M | -628.39M | 665.37M | -304.59M | -84.01M |
| Change in Receivables | 0 | 0 | 0 | 0 | -773.08M | 770.04M | -565K | -6.51M |
| Change in Inventory | 0 | 0 | 0 | 0 | 52.81M | 0 | 0 | 0 |
| Change in Payables | 2.01M | 1.47M | 964K | -790K | -171K | 797K | 732K | -988K |
| Cash from Investing | -29.99M | -60.44M | -256.16M | -9.86M | -140.81M | -1.19B | 164.73M | 499.37M |
| Capital Expenditures | -2.74M | -8.19M | -8.94M | -6.55M | -21.82M | -68.01M | -21.57M | -7.3M |
| CapEx % of Revenue | 18.4% | 9.44% | 12.57% | 0.1% | 0.02% | 0.04% | 0.25% | 0.1% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.74M | 0 | 180K | -140.81M | 0 | 0 | 0 |
| Cash from Financing | 271.18M | 24.98M | 449.24M | 529.47M | 100.33M | 34.76M | 7.38M | 4.39M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 584K | 1.13M | -189K | 15.38M | 6.56M | -100K | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -69.12M | -102.29M | -138.57M | -197.49M | -69.41M | 1.6B | -800.36M | -453.65M |
| FCF Margin % | -463.91% | -117.84% | -194.9% | -2.94% | -0.06% | 0.99% | -9.29% | -6.11% |
| FCF Growth % | - | -0.48% | -0.35% | -0.43% | 0.65% | 23.98% | -1.5% | 0.43% |
| FCF per Share | -9.91 | -1.06 | -1.29 | -1.66 | -0.52 | 11.83 | -5.97 | -3.33 |
| FCF Conversion (FCF/Net Income) | 0.95x | 0.81x | 0.74x | 0.64x | -0.09x | 3.22x | 1.27x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 252.03M | 0 | 786K |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -142.74% | -52.36% | 49.2% | 29.39% | -33.53% | -38.09% |
| Return on Invested Capital (ROIC) | - | - | -271.84% | -66.96% | 40.15% | 48.46% | -36.26% | -35.25% |
| Gross Margin | -41854.36% | -11447.12% | 100% | 100% | 53.09% | 61.57% | -564.69% | -545.03% |
| Net Margin | -46880.54% | -13350.69% | -24568.64% | -444.14% | 48.25% | 31.92% | -713.69% | -703.4% |
| Debt / Equity | - | - | 0.00x | 0.10x | 0.10x | 0.06x | 0.08x | 0.09x |
| FCF Conversion | 0.95x | 0.81x | 0.74x | 0.64x | -0.09x | 3.22x | 1.27x | 0.86x |
| Revenue Growth | - | 482.55% | -18.09% | 9357.81% | 1528.99% | 47.51% | -94.67% | -13.9% |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Contract Revenue | - | - | 169.87M | 52.71M | 2.23M | 55.33M |
| Contract Revenue Growth | - | - | - | -68.97% | -95.77% | 2383.53% |
| Grant | 900K | - | - | - | 46.69M | 10.49M |
| Grant Growth | - | - | - | - | - | -77.52% |
| Collaboration Revenue | - | - | 917.19M | 1.51B | 37.27M | 8.38M |
| Collaboration Revenue Growth | - | - | - | 64.14% | -97.52% | -77.52% |
| License Revenue | - | - | - | - | - | - |
| License Revenue Growth | - | - | - | - | - | - |
| License | - | 22.75M | - | 22.29M | - | - |
| License Growth | - | - | - | - | - | - |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Non-US | - | - | - | - | - | 60.31M |
| Non-US Growth | - | - | - | - | - | - |
| UNITED STATES | - | - | - | - | - | 11.53M |
| UNITED STATES Growth | - | - | - | - | - | - |
Vir Biotechnology, Inc. (VIR) reported $16.9M in revenue for fiscal year 2024. This represents a 11215% increase from $0.1M in 2017.
Vir Biotechnology, Inc. (VIR) saw revenue decline by 13.9% over the past year.
Vir Biotechnology, Inc. (VIR) reported a net loss of $499.7M for fiscal year 2024.
Vir Biotechnology, Inc. (VIR) has a return on equity (ROE) of -38.1%. Negative ROE indicates the company is unprofitable.
Vir Biotechnology, Inc. (VIR) had negative free cash flow of $460.4M in fiscal year 2024, likely due to heavy capital investments.